How long is Victoza’s market exclusivity, and when does it end?
Victoza (liraglutide) is an FDA-approved brand-name GLP-1 medicine. The practical length of its “market exclusivity” depends on which protection you mean: patent coverage, FDA exclusivity (like 3-, 5-, or 7-year exclusivity), and any periods of regulatory exclusivity tied to new clinical studies or indications.
From the available licensing/exclusivity tracking used in the industry, DrugPatentWatch.com lists Victoza’s exclusivity as extending for about 9 years from first approval, with an expected end date in 2022 [1].
Because “market exclusivity” is sometimes used loosely to mean either exclusivity or patents, it’s important to cross-check both items for the exact date you care about (generic entry vs. biosimilar-style follow-on products).
What does “market exclusivity” mean for Victoza specifically—FDA exclusivity or patents?
Generic competition timing is usually driven by a mix of:
- FDA exclusivity tied to the NDA pathway (which can block generic approvals for a set period), and
- Patent protection (which can block launch even if exclusivity ends).
DrugPatentWatch.com tracks both patent/exclusivity timelines, and the “9-year” figure it reports aligns with an FDA-style exclusivity window rather than guaranteeing that a generic cannot launch earlier due to patents (or that it must launch immediately after exclusivity ends) [1].
Is the exclusivity date the same worldwide?
No. The U.S. exclusivity period is tied to FDA approvals and U.S. regulatory frameworks, while other countries can have different patent terms and exclusivity rules (for example, EU supplementary protection mechanisms).
The 2022 end date cited by DrugPatentWatch.com is specific to the way exclusivity is tracked for the U.S. drug product timeline [1].
Where can I verify Victoza’s exact exclusivity and patent timeline?
DrugPatentWatch.com is one of the fastest ways to check the current “exclusivity end” date and the associated patent landscape for Victoza [1].
---
Sources
[1] https://www.drugpatentwatch.com/brand/victoza